低危HPV相关口咽癌放疗联合每周顺铂或西妥昔单抗的随机试验(TROG 12.01)
TROG 12.01随机多中心试验纳入189例低危HPV相关口咽鳞癌患者,比较放疗联合每周顺铂或西妥昔单抗。主要终点症状严重程度无差异,但西妥昔单抗组3年无失败生存率显著更低(80% vs 93%),毒性未改善。放疗联合顺铂仍是标准治疗。
核心结论
- 对于低危HPV相关口咽癌,放疗联合西妥昔单抗相比联合每周顺铂无失败生存更差,且症状负担和毒性未改善,放疗联合顺铂仍是标准治疗。
研究设计与样本
- TROG 12.01为随机、多中心试验,在澳大利亚和新西兰15个中心入组189例HPV相关口咽鳞癌患者,按1:1随机接受放疗(70 Gy/35次)联合每周顺铂(40 mg/m2,共7次)或西妥昔单抗(负荷400 mg/m2后每周250 mg/m2,共7次)。
- 主要终点为基线至放疗完成后13周MD Anderson症状量表头颈症状严重程度评分曲线下面积。
关键数值与推荐
- 入组标准为HPV相关口咽鳞癌,AJCC第7版III期(排除T1-2N1)或IV期(排除T4和/或N3和/或N2b-c且吸烟史>10包年,和/或远处转移)。
- 放疗剂量为70 Gy分35次,顺铂为每周40 mg/m2共7次,西妥昔单抗为负荷400 mg/m2后每周250 mg/m2共7次。
临床怎么用
- 低危HPV相关口咽癌患者不应以放疗联合西妥昔单抗替代放疗联合每周顺铂,因生存更差且毒性未改善。
- 放疗联合每周顺铂应继续作为该人群的标准治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The excellent prognosis of patients with low-risk human papillomavirus (HPV)- associated oropharyngeal squamous cell carcinoma has led to concerns about overtreatment and excessive toxicity with radiation therapy and cisplatin, leading to interest in de-intensification trials. We investigated whether cetuximab, an epidermal growth factor receptor targeting antibody, when combined with radiation therapy would result in a decrease in symptom burden and toxicity with similar efficacy compared with weekly cisplatin. METHODS AND MATERIALS: TROG12.01, a randomized, multicenter trial involving 15 sites in Australia and New Zealand enrolled patients with HPV-associated oropharyngeal squamous cell carcinoma, American Joint Committee on Cancer 7th edition stage III (excluding T1-2N1) or stage IV (excluding T4 and/or N3 and/or N2b-c if smoking history >10 pack years and/or distant metastases). Patients were randomized (1:1) to receive radiation therapy (70 Gy in 35 fractions) with either weekly cisplatin, 7 doses of 40 mg/m2, or cetuximab, loading dose of 400 mg/m2 followed by 7 weekly doses of 250 mg/m2. The primary outcome was symptom severity assessed by the MD Anderson Symptom Inventory Head and Neck Symptom Severity Scale from baseline to 13 weeks postcompletion of radiation therapy using the area under the curve. Trial was registered on ClinicalTrials.gov: NCT01855451. RESULTS: Between June 17, 2013, and June 7, 2018, 189 patients were enrolled, with 92 in cisplatin arm and 90 in cetuximab included in the main analysis. There was no difference in the primary endpoint of symptom severity; difference in area under the curve cetuximab-cisplatin was 0.05 (95% confidence interval [CI], -0.19, 0.30), P = .66. The T-score (mean number of ≥grade 3 acute adverse events) was 4.35 (standard deviation 2.48) in the cisplatin arm and 3.82 (standard deviation 1.8) in the cetuximab arm, P = .108. The 3-year failure-free survival rates were 93% (95% CI, 86%-97%) in the cisplatin arm and 80% (95% CI, 70%-87%) in the cetuximab arm (hazard ratio = 3.0 [95% CI, 1.2-7.7]); P = .015. CONCLUSIONS: For patients with low-risk HPV-associated oropharyngeal cancer, radiation therapy and cetuximab had inferior failure-free survival without improvement in symptom burden or toxicity compared with radiation therapy and weekly cisplatin. Radiation therapy and cisplatin remain the standard of care.
引用
- Rischin D, King M, Kenny L, et al. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study. Int J Radiat Oncol Biol Phys. 2021. PMID: 34098030. doi:10.1016/j.ijrobp.2021.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。